Group | Sub-group | Number completed | |
---|---|---|---|
Male | Female | ||
FGDs | |||
Treatment recipients | A (HIV-positive, receiving ARVs, completed participation in clinical controlled study of Alu efficacy and safety | 1 | 3 |
B (HIV-negative, no ARV, completed participation in clinical controlled study of ALu efficacy and safety) | 2 | 2 | |
C (HIV-positive, receiving ARVs, excluded from participation in clinical study) | 1 | 4 | |
IDIs | |||
Health workers | Clinical study staff | 4 | |
HIV Care and Treatment Clinic health workers | 4 | ||
Hospital health workers | 2 |